Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b and meningococcal group c conjugate vaccine + measles, mumps and rubella vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The Hib-MenC-TT conjugate vaccine + MMR vaccine refers to the concomitant administration of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (marketed as Menitorix) with a measles, mumps, and rubella (MMR) vaccine (marketed as Priorix). Developed by GSK, this combination is typically administered as a booster dose in toddlers aged 12-15 months to provide simultaneous protection against five major pediatric infectious diseases. The Hib-MenC-TT component utilizes purified capsular polysaccharides from Hib and MenC bacteria, each conjugated to a tetanus toxoid carrier protein to enhance immunogenicity and induce T-cell dependent memory. The MMR component consists of live attenuated measles, mumps, and rubella viruses that replicate to stimulate long-lasting humoral and cellular immunity. Clinical trials have demonstrated that these vaccines can be safely co-administered without significant interference in immune responses or increased safety concerns compared to separate administration.
- Brand names
- MenitorixPriorix
- Other names
- Hib-MenC-TT + MMR vaccineHib-MenC-TT conjugate vaccine + MMR vaccineMenitorix + Priorix
02
Targets
MV (Measles virus)Mumps virus antigenNeisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)
Beyond the preview
Go deeper on haemophilus influenzae type b and meningococcal group c conjugate vaccine + measles, mumps and rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b and meningococcal group c conjugate vaccine + measles, mumps and rubella vaccine.